Brought to you by 
Genomic Health gets exclusive rights to sell Epic's liquid biopsy test in the US
14 Sep 2020
Executive Summary
Epic Sciences Inc. granted Genomic Health Inc. exclusive rights to sell its ARV7 liquid biopsy test in the US to assist in treatment planning in patients with metastatic castration-resistant prostate cancer (mCRPC).
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genomic Health gets exclusive rights to sell Epic's liquid biopsy test in the US
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice